Ruti Aga's Six-Year Ban: A Forged Prescription, a Clinic That Never Existed, and the Career Line of a 2:18 Marathoner

The prescription listed knee synovitis, an intra-articular injection, and the drug methylprednisolone. The 'doctor' who wrote it was a family member with no medical registration. The clinic printed on the letterhead never existed. And when asked where the pad came from, the answer was 'an old prescription pad left over from a former workplace' — a claim the clinic itself flatly disowned. Three independent verification points, three identical answers. Since 10 September, a six-year clock has been running on Ruti Aga, and it is running not for the substance found in her body but for the paper she produced to explain it.

The Athletics Integrity Unit's statement on Thursday splits the sanction cleanly in two: two years for the presence of a prohibited substance, four years for tampering. The sum is six. That arithmetic is the sharpest number in the case, and the least discussed fact is that the drug anchoring those six years has no proven endurance benefit at all.

The March race and the clock from 10 September

Aga is an Ethiopian marathoner, 32 years old. She belongs to the generation that touched the top layer of women's marathon running across the 2026-19 seasons. Public records list 2:18:34 for second place in Berlin 2026 and 2:20:40 for the win in Tokyo 2026; those figures come from public databases rather than the original report, so treat them with the same caution I am applying. What is documented is the Tokyo title and three runner-up finishes at World Marathon Majors.

In March she won a half marathon in China. The report names neither the race, the time, the field depth nor clearly the year, but the logic of the AIU investigation implies a World Athletics Label-tier road race with in-competition testing. Methylprednisolone was found in the sample taken there. What followed divides into three parts: the sample, the explanation, and the documentation of that explanation. The third part is the real subject.

In 32 years of covering this sport I have seen one pattern return again and again in road-running doping cases. The first statement is almost never true, but the first statement always points at a structural gap. In Aga's case that gap is this: a 2:18 marathoner had no credentialed team physician, no TUE process, and a routine knee injection was solved inside the family. That is one athlete's negligence, and it is also a photograph of an entire system.

Two plus four: the arithmetic of the sanction

Under the 2026 WADA Code the standard sanction for presence is four years, reduced to two where the substance is Specified and intent is not established. Aga's two years came down that path. Then four years for tampering, the Code's standard tampering sanction.

Three things follow from the sum. The panel accepted that she did not take the drug with intent to enhance performance, which is why presence was not sanctioned at the maximum. The panel rejected No Significant Fault or Negligence, which would have pushed the presence sanction far below two years, potentially to a reprimand. And the forged prescription is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction; it entered only as a separate charge.

There is a technicality here that forms the legal hinge of the whole case, and nearly every report has got it wrong.

S9 versus S1: what the substance is, and what it was sold as

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, not S1. That difference is not a difference in sentencing language; it is a difference in the direction of the entire defence. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection administered out-of-competition is entirely legal.

The consequence is that the question in this case was never 'did she take a steroid'. The questions were route and timing. In road races the in-competition testing window opens at 23:59 the day before the race, so an injection given days earlier becomes a violation if residues are present on race day. That is technical, and that technicality is the door to a legitimate defence.

Three things were needed to walk through it. Genuine medical records documenting the knee examination, the injection date and the dose. A doctor whose registration could be verified. A clear timeline showing residues were not expected to persist, or a TUE application where needed. None of it existed, which is precisely why paper was manufactured.

That is the case's largest lesson: the athlete destroyed the one defence that could have worked. A glucocorticoid case is won on documents, and here the document was false.

The prescription chain: three verification points, three failures

The chain broke in three places. The clinic on the letterhead did not exist. The person who wrote the prescription was a family member absent from any medical register. And the explanation for the pad's origin was disowned by the clinic itself.

The four-year tampering charge did not come from the document alone. It came from statements made during the investigation, meaning from an interview. That detail matters, because language and translation conditions in AIU interviews have been a recurring point of contention, particularly with East African athletes. When an athlete is questioned in a language other than her own, without counsel present, about technical documents, the distance between statement and fact widens on its own. This does not weaken the charge, but it explains the room in which tampering charges are built.

Results, prize money and rankings: what actually goes

The report does not state the scope of the decision. AIU standard practice is clear, however: the result of the competition where the sample was collected is automatically disqualified, along with its prize money, and ranking points accrued from that date are lost. The March win, its title and its money are all in question.

By contrast, the 2026 Tokyo title and the three Major runner-up finishes do not automatically disappear. Absent evidence of earlier use, results before that date are not annulled. The distinction matters, because social media has read this as the erasure of an entire record. The record survives; the road ahead does not. Those are different things.

From 32 to 38: the career arithmetic

Aga is 32. A six-year ban from 10 September puts a return at roughly 38. In women's marathon running, a return at 38 is not impossible — I have watched excellent marathon running at 38 and 40 in this sport. For Ethiopia, it is close to impossible.

The depth of Ethiopian women's marathon running is such that a 2:18 performer cannot treat national selection as guaranteed. Returning at 38 with a doping record in that environment is not merely a physical challenge; it is selection arithmetic. No federation will spend a slot on her when a rival ten years younger and uncontroversial is available.

In practice, six years is a career sanction. And it is a sanction for paper, not for a substance with no established endurance benefit.

China's label-race circuit: appearance fees and the testing economy

The overlooked part is this. The March race was in China, it was a half marathon, and she won it. For East African marathoners, China's label-race circuit is a clean economic model: decent appearance fees between Majors, limited competition, contained risk. For a 2:18-2:20 runner it is the ideal template — a few Majors a year, a handful of Asian label races in between.

That same circuit is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races. Where the money is large, the elite field is large; where the elite field is large, the testing is there. That collision will intensify, and the cost will fall first on runners who lack the structure to protect them from it.

Contrarian: calling it a steroid is the biggest error

The most common media error is the classification repeated in nearly every headline — that this was a steroid, that WADA classes it as performance enhancing. Both statements are wrong. Methylprednisolone is a glucocorticoid, class S9, prohibited in-competition only, with no proven endurance benefit.

The error is not innocent. Presenting an S9 case as though it were an S1 case tells the reader there is a performance-gain story here, when the story is about medical governance. Two harms follow. The athlete is demonised beyond the facts. And the real question — why did this athlete have no credentialed doctor — gets buried.

A harder question deserves an answer. Six years for a drug with no established endurance benefit: is that proof of AIU rigour, or of uneven enforcement against African road runners? My answer is that the question is being asked in the wrong place. The six years came from paper, not from the drug. Had Aga arrived with genuine medical records, there may have been no case at all. The disparity is not in the length of the sanction; it is in the support structure.

This is where gender enters. In East African road-running clusters, women athletes often work inside the same agent-coach-camp structures where medical support is informal and knee pain is something to run through. When I launched my newsletter in 2026, working through the numbers from the Asian Athletics Championships in Bhubaneswar, one figure stood out: Indian women won 12 of the country's 29 medals and received 18 per cent of media mentions. The gap between podium and attention, and the gap between podium and medical support, are two sides of the same coin. An athlete who cannot get column space also waits longer for a team physician.

The attention audit: headlines for scandal, not for sport

I have logged one simple thing for years: when women's road racing gets covered. The answer is blunt. A record earns two days. A positive test earns two weeks. The same audit applies here. Aga's 2026 Tokyo win received far less space than this six-year ban.

I am not objecting. This is necessary news. But put the two numbers side by side and a third question appears: if women's road racing generates stories only in crisis, who holds the sport's structure accountable? A federation that does not provide team physicians to its runners should be criticised on the day those runners win.

What comes next

One date remains: the CAS appeal window, typically about 21 days from the reasoned decision. Appeal risk is low, because the forgery finding is document-based and hard to overturn. Another route is open and undiscussed — document forgery is also a criminal matter, outside AIU jurisdiction. Whether the case was referred to a national authority is not in the statement.

My ask is small and concrete, because small asks get answered. The Ethiopian federation and the AIU should publish two things: the list of camps with a registered team physician attached, and the share of athletes with a recorded TUE application. Neither names an individual, and together they would show how large the problem is.

The clock from 10 September is ringing for Ruti Aga. It should also reach the hundreds of runners who will line up next season on the same label-race circuit, inside the same informal medical structure, carrying the same knee pain. The question is not whether they will be sanctioned. It is whether anyone will give them the doctor who makes the sanction unnecessary.